Differences in GPR30 Regulation by Chlorotriazine Herbicides in Human Breast Cells

Biochemistry Research International

Volumn 2016, Issue , 2016, Pages

  Florian, Colin P ^a   Mansfield, Shelly R ^a   Schroeder, Jennifer R ^a  

^a MILLIKIN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84959387762     PISSN: 20902247     EISSN: 20902255     Source Type: Journal    
DOI: 10.1155/2016/2984081     Document Type: Article

References (63)

1. M. C. R. Alavanja, M. K. Ross, and M. R. Bonner, "Increased cancer burden among pesticide applicators and others due to pesticide exposure," CA: A Cancer Journal for Clinicians, vol. 63, no. 2, pp. 120-142, 2013.
2. R. Ferro, A. Parvathaneni, S. Patel, and P. Cheriyath, "Pesticides and breast cancer," Advances in Breast Cancer Research, vol. 1, no. 3, pp. 30-35, 2012.
3. L. Albanito, R. Lappano, A. Madeo et al., "G-Protein-coupled receptor 30 and estrogen receptor- are involved in the proliferative effects induced by atrazine in ovarian cancer cells," Environmental Health Perspectives, vol. 116, no. 12, pp. 1648-1655, 2008.
4. W. J. Hayes and E. R. Laws, Handbook of Pesticide Toxicology, Academic Press, San Diego, Calif, USA, 1991.
5. U. S. E. P. Agency, Health Advisory Summary: Cyanazine, Office of Drinking Water, U. S. Environmental Protection Agency, Washington, DC, USA, 1988.
6. A. M. Fan andG. V. Alexeeff, Public Health Goal for Simazine in Drinking Water, vol. 40, CEPA Office of Environmental Health Hazard Assessment, 2001.
7. M. Silva and P. Iyer, "Toxicity endpoint selections for a simazine risk assessment," Birth Defects Research Part B: Developmental and Reproductive Toxicology, vol. 101, no. 4, pp. 308-324, 2014.
8. L. Albanito, A. Madeo, R. Lappano et al., "G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells," Cancer Research, vol. 67, no. 4, pp. 1859-1866, 2007.
9. S. Chakrabarti and S. T. Davidge, "G-protein coupled receptor 30 (GPR30): A novel regulator of endothelial inflammation," PLoS ONE, vol. 7, no. 12, Article IDe52357, 2012.
10. M. Maggiolini and D. Picard, "The unfolding stories of GPR30, a new membrane-bound estrogen receptor," Journal of Endocrinology, vol. 204, no. 2, pp. 105-114, 2010.
11. C. M. Revankar, H. D. Mitchell, A. S. Field et al., "Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30," ACS Chemical Biology, vol. 2, no. 8, pp. 536-544, 2007.
12. E. J. Filardo, J. A. Quinn, A. Raymond Frackelton Jr., and K. I. Bland, "Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis," Molecular Endocrinology, vol. 16, no. 1, pp. 70-84, 2002.
13. R. Girgert, G. Emons, and C. Gründker, "Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17-estradiol," BMC Cancer, vol. 14, p. 935, 2014.
14. A. Vivacqua, E. Romeo, P. De Marco, E. M. De Francesco, S. Abonante, and M. Maggiolini, "GPER mediates the Egr-1 expression induced by 17beta-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells," Breast Cancer Research and Treatment, vol. 133, no. 3, pp. 1025-1035, 2012.
15. M. R. Cronan, K. Nakamura, N. L. Johnson et al., "Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis," Oncogene, vol. 31, no. 34, pp. 3889-3900, 2012.
16. A. L. Scaling, E. R. Prossnitz, and H. J. Hathaway, "Gper mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast," Hormones and Cancer, vol. 5, no. 3, pp. 146-160, 2014.
17. A. M. Wróbel and E. . Gregoraszczuk, "Action of methyl-, propyl-and butylparaben on GPR30 gene and protein expression, cAMP levels and activation of ERK1/2 and PI3K/Akt signaling pathways in MCF-7 breast cancer cells and MCF-10A non-transformed breast epithelial cells," Toxicology Letters, vol. 238, no. 2, pp. 110-116, 2015.
18. J. D. Rich, S. M. Gabriel, and J. R. Schultz-Norton, "In vitro effects of herbicides and insecticides on human breast cells," ISRN Toxicology, vol. 2012,Article ID 232461, 9 pages, 2012.
19. R. Girgert, G. Emons, and C. Gründker, "Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy," Breast Cancer Research and Treatment, vol. 134, no. 1, pp. 199-205, 2012.
20. K. J. Livak and T. D. Schmittgen, "Analysis of relative gene expression data using real-time quantitative pcr and the 2 T method," Methods, vol. 25, no. 4, pp. 402-408, 2001.
21. J. O'Brien, I. Wilson, T. Orton, and F. Pognan, "Investigation of the alamar blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity," European Journal of Biochemistry, vol. 267, no. 17, pp. 5421-5426, 2000.
22. C. Carmeci, D. A. Thompson, H. Z. Ring, U. Francke, and R. J. Weigel, "Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer," Genomics, vol. 45, no. 3, pp. 607-617, 1997.
23. C. M. Revankar,D. F. Cimino, L. A. Sklar, J. B. Arterburn, and E. R. Prossnitz, "A transmembrane intracellular estrogen receptor mediates rapid cell signaling," Science, vol. 307, no. 5715, pp. 1625-1630, 2005.
24. P. Thomas, Y. Pang, E. J. Filardo, and J. Dong, "Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells," Endocrinology, vol. 146, no. 2, pp. 624-632, 2005.
25. G. Langer, B. Bader, L. Meoli et al., "A critical review of fundamental controversies in the field of GPR30 research," Steroids, vol. 75, no. 8-9, pp. 603-610, 2010.
26. E. R. Levin, "Minireview: extranuclear steroid receptors: roles in modulation of cell functions," Molecular Endocrinology, vol. 25, no. 3, pp. 377-384, 2011.
27. D. P. Pandey, R. Lappano, L. Albanito, A. Madeo, M. Maggiolini, and D. Picard, "Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF," The EMBO Journal, vol. 28, no. 5, pp. 523-532, 2009.
28. E. A. Ariazi, E. Brailoiu, S. Yerrumet al., "TheGprotein-coupled receptor GPR30 inhibits proliferation of estrogen receptorpositive breast cancer cells," Cancer Research, vol. 70, no. 3, pp. 1184-1194, 2010.
29. L. Albanito, D. Sisci, S. Aquila et al., "Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells," Endocrinology, vol. 149, no. 8, pp. 3799-3808, 2008.
30. M. Maggiolini, A. Vivacqua, G. Fasanella et al., "The G proteincoupled receptor GPR30 mediates c-fos up-regulation by 17-estradiol and phytoestrogens in breast cancer cells," The Journal of Biological Chemistry, vol. 279, no. 26, pp. 27008-27016, 2004.
31. Y. Berthois, J. A. Katzenellenbogen, and B. S. Katzenellenbogen, "Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture," Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 8, pp. 2496-2500, 1986.
32. J. E. Moreno-Cuevas and D. A. Sirbasku, "Estrogen mitogenic action. III. Is phenol red a 'red herring'?" In Vitro Cellular and Developmental Biology-Animal, vol. 36, no. 7, pp. 447-464, 2000.
33. C. F. Holinka, Y. Anzai, H. Hata, N. Kimmel, H. Kuramoto, and E. Gurpide, "Proliferation and responsiveness to estrogen of human endometrial cancer cells under serum-free culture conditions," Cancer Research, vol. 49,no. 12,pp. 3297-3301, 1989.
34. T. E. Wiese, L. G. Kral, K. E. Dennis, W. B. Butler, and S. C. Brooks, "Optimization of estrogen growth response in MCF-7 cells," In Vitro Cellular and Developmental Biology, vol. 28, no. 9-10, pp. 595-602, 1992.
35. K. Connor, J. Howell, I. Chen et al., "Failure of Chloro-S-triazine-derived compounds to induce estrogen receptormediated responses in vivo and in vitro," Toxicological Sciences, vol. 30, no. 1, pp. 93-101, 1996.
36. L. Albanito, R. Lappano, A. Madeo et al., "Effects of atrazine on estrogen receptor alpha-and g protein-coupled receptor 30-mediated signaling and proliferation in cancer cells and cancerassociated fibroblasts," Environmental Health Perspectives, vol. 123, pp. 493-499, 2015.
37. I. de la Casa-Resino, J. M. Navas, and M. L. Fernández-Cruz, "Chlorotriazines do not activate the aryl hydrocarbon receptor, the oestrogen receptor or the thyroid receptor in in vitro assays," Alternatives to Laboratory Animals, vol. 42, no. 1, pp. 25-30, 2014.
38. P. D. Darbre, "Hypersensitivity and growth adaptation of oestrogen-deprived MCF-7 human breast cancer cells," Anticancer Research, vol. 34, no. 1, pp. 99-105, 2014.
39. P. A. Jones, V. A. Baker, A. Irwin, and L. K. Earl, "Modulation of MCF-7 cell proliferative responses by manipulation of assay conditions," Toxicology in Vitro, vol. 11, no. 6, pp. 769-773, 1997.
40. A. M. Jesionowski, S. M. Gabriel, J. D. Rich, and J. R. Schroeder, "Failure of pesticides to alter migration of cancerous and noncancerous breast cell lines in vitro," Toxicology Research, vol. 4, no. 1, pp. 99-105, 2015.
41. H.-J. Luo, P. Luo, G.-L. Yang, Q.-L. Peng, M.-R. Liu, and G. Tu, "G-protein coupled estrogen receptor 1 expression in primary breast cancers and its correlation with clinicopathological variables," Journal of Breast Cancer, vol. 14, no. 3, pp. 185-190, 2011.
42. F. Gao,X. Ma, A. B. Ostmann, and S. K. Das, "GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and Estrogen receptor alpha (ER) phosphorylation signals," Endocrinology, vol. 152, no. 4, pp. 1434-1447, 2011.
43. E. M. De Francesco, M. Pellegrino, M. F. Santolla et al., "GPER mediates activation of hif1alpha/VEGF signaling by estrogens," Cancer Research, vol. 74, no. 15, pp. 4053-4064, 2014.
44. A. Vivacqua, R. Lappano, E. M. De Francesco, P. DeMarco, and M. Maggiolini, "Multifactorial regulation of GPER expression in cancer cells and cardiomyocytes," Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, vol. 11, no. 4, pp. 235-242, 2011.
45. E. A. Ariazi, J. L. Ariazi, F. Cordera, andV. C. Jordan, "Estrogen receptors as therapeutic targets in breast cancer," Current Topics in Medicinal Chemistry, vol. 6, no. 3, pp. 181-202, 2006.
46. M. Skrzypczak, S. Schüler, C. Lattrich, A. Ignatov, O. Ortmann, and O. Treeck, "G protein-coupled estrogen receptor (GPER) expression in endometrial adenocarcinoma and effect of agonist G-1 on growth of endometrial adenocarcinoma cell lines," Steroids, vol. 78, no. 11, pp. 1087-1091, 2013.
47. P. B. Tchounwou, B. A. Wilson, A. B. Ishaque, and J. Schneider, "Atrazine potentiation of arsenic trioxide-induced cytotoxicity and gene expression in human liver carcinoma cells (HepG2)," Molecular and Cellular Biochemistry, vol. 222, no. 1-2, pp. 49-59, 2001.
48. E. R. Prossnitz and M. Barton, "Estrogen biology: new insights into GPER function and clinical opportunities," Molecular and Cellular Endocrinology, vol. 389, no. 1-2, pp. 71-83, 2014.
49. E. R. Prossnitz and M. Maggiolini, "Mechanisms of estrogen signaling and gene expression via GPR30," Molecular and Cellular Endocrinology, vol. 308, no. 1-2, pp. 32-38, 2009.
50. H. Buteau-Lozano, G. Velasco, M. Cristofari, P. Balaguer, and M. Perrot-Applanat, "Xenoestrogens modulate vascular endothelial growth factor secretion in breast cancer cells through an estrogen receptor-dependent mechanism," Journal of Endocrinology, vol. 196, no. 2, pp. 399-412, 2008.
51. H. O. Smith, H. Arias-Pulido, D. Y. Kuo et al., "GPR30 predicts poor survival for ovarian cancer,"GynecologicOncology, vol. 114, no. 3, pp. 465-471, 2009.
52. H. O. Smith, K. K. Leslie,M. Singh et al., "GPR30: A novel indicator of poor survival for endometrial carcinoma," American Journal of Obstetrics & Gynecology, vol. 196, no. 4, pp. 386. e1-386. e11, 2007.
53. E. J. Filardo, C. T. Graeber, J. A. Quinn et al., "Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its associationwith clinicopathologic determinants of tumor progression," Clinical Cancer Research, vol. 12, no. 21, pp. 6359-6366, 2006.
54. E. R. Levin, "Integration of the extranuclear and nuclear actions of estrogen," Molecular Endocrinology, vol. 19, no. 8, pp. 1951-1959, 2005.
55. G. Castoria, A. Migliaccio, A. Bilancio et al., "PI3-kinase in concert with Src promotes the S-phase entry of oestradiolstimulated MCF-7 cells," The EMBO Journal, vol. 20, no. 21, pp. 6050-6059, 2001.
56. G. Castoria,A. Migliaccio, M. DiDomenico et al., "Role of atypical protein kinase C in estradiol-triggered G1/S progression of MCF-7 cells," Molecular and Cellular Biology, vol. 24, no. 17, pp. 7643-7653, 2004.
57. R. J. Santen, R. X. Song, R. McPherson et al., "The role of mitogen-activated protein (MAP) kinase in breast cancer," Journal of Steroid Biochemistry and Molecular Biology, vol. 80, no. 2, pp. 239-256, 2002.
58. R. X.-D. Song, R. A. McPherson, L. Adam et al., "Linkage of rapid estrogen action toMAPK activation by ER-Shc association and Shc pathway activation,"Molecular Endocrinology, vol. 16, no. 1, pp. 116-127, 2002.
59. Z. Zhang, B. Maier, R. J. Santen, and R. X.-D. Song, "Membrane association of estrogen receptor a mediates estrogen effect on MAPK activation," Biochemical and Biophysical Research Communications, vol. 294, no. 5, pp. 926-933, 2002.
60. M. B. Martin, M. Saceda, and R. K. Lindsey, "Regulation of estrogen receptor expression in breast cancer," Advances in Experimental Medicine and Biology, vol. 330, pp. 143-153, 1993.
61. M. Borrás, L. Hardy, F. Lempereur et al., "Estradiol-induced down-regulation of estrogen receptor. Effect of various modulators of protein synthesis and expression," Journal of Steroid Biochemistry and Molecular Biology, vol. 48, no. 4, pp. 325-336, 1994.
62. J. J. Pink and V. C. Jordan, "Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines," Cancer Research, vol. 56, no. 10, pp. 2321-2330, 1996.
63. E. A. Vladusic, A. E. Hornby, F. K. Guerra-Vladusic, J. Lakins, and R. Lupu, "Expression and regulation of estrogen receptor beta in human breast tumors and cell lines," Oncology Reports, vol. 7, no. 1, pp. 157-167, 2000.